Role of Toll-like receptors in adjuvant-augmented immune therapies.
about
Role of TOLL-like Receptors in Adjuvant-Augmented Immune Therapies by T. SeyaRegulatory T cells, a potent immunoregulatory target for CAM researchers: the ultimate antagonist (I).Toll Like Receptors Signaling Pathways as a Target for Therapeutic InterventionsEffective transcutaneous immunization by antigen-loaded flexible liposome in vivo.Advances in FIV vaccine technology.TLR3 activation efficiency by high or low molecular mass poly I:C.Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.Transcutaneous vaccines--current and emerging strategies.Toll-like receptors' pathway disturbances are associated with increased susceptibility to infections in humans.Molecular cloning of Salmo salar Toll-like receptors (TLR1, TLR22, TLR5M and TLR5S) and expression analysis in SHK-1 cells during Piscirickettsia salmonis infection.Coadministration of the fungal immunomodulatory protein FIP-Fve and a tumour-associated antigen enhanced antitumour immunity.c-Jun N-terminal kinase 1 is required for Toll-like receptor 1 gene expression in macrophages.Immunostimulatory effect of salmon prolactin on expression of Toll-like receptors in Oncorhynchus mykiss infected with Piscirickettsia salmonis.Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation.TLR3 and TLR4 are innate antiviral immune receptors in human microglia: role of IRF3 in modulating antiviral and inflammatory response in the CNS.Regulation of Cellular Metabolism and Cytokines by the Medicinal Herb Feverfew in the Human Monocytic THP-1 Cells.Induction of type I interferons and interferon-inducible Mx genes during respiratory syncytial virus infection and reinfection in cotton rats.Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction.Aureobasidium pullulans-cultured fluid induces IL-18 production, leading to Th1-polarization during influenza A virus infection.
P2860
Q25257758-78D89309-6192-4C18-BD76-83FE63CAE186Q25257769-1696B948-66B2-4CBF-BFE4-A6C9E11E8109Q29248835-3EC60B94-55FC-4CFC-86CF-B3B95544D4A7Q35656890-4763EBF5-B3B6-4C84-AA0E-56A4E96719D7Q36634847-B9CFFF12-B965-4ED5-ACA9-B91E63CA73DCQ37616611-75FE7AE2-305F-49C3-8BB8-5C5D26B500FEQ37773237-21B10C32-DFD6-4636-A514-0855263BE6D9Q38073800-2F99DE55-BCF7-4E56-B59E-DDBA62B50E34Q38140711-5BB27DCC-C6E8-4DE4-8597-F206C13F545AQ38883383-5E7F6819-DF30-4850-A947-C94DE08DBA1DQ39796145-F89FDAC9-3C4C-4637-9A99-483C9B5F2C8CQ40100429-1DB2E710-C0B9-4572-8D15-00024C0B763FQ40922517-234EA1E3-274D-40BB-9960-AB90AFED122FQ41937286-78891C49-5F5C-4979-AC21-8B745DA5D171Q42155544-6EAEFB73-F6D3-4D3D-B744-FB07BB0F4AB7Q42183551-48D82460-5920-4FB4-AE48-0C0083433491Q42551081-200DE146-BE09-4558-B057-ACE10DBA66A8Q45074067-9E750736-7308-41C4-AE41-6005EE5D5E73Q45326263-1E01F5F3-75E3-48C1-BB89-998094987FE6
P2860
Role of Toll-like receptors in adjuvant-augmented immune therapies.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Role of Toll-like receptors in adjuvant-augmented immune therapies
@nl
Role of Toll-like receptors in adjuvant-augmented immune therapies.
@ast
Role of Toll-like receptors in adjuvant-augmented immune therapies.
@en
type
label
Role of Toll-like receptors in adjuvant-augmented immune therapies
@nl
Role of Toll-like receptors in adjuvant-augmented immune therapies.
@ast
Role of Toll-like receptors in adjuvant-augmented immune therapies.
@en
prefLabel
Role of Toll-like receptors in adjuvant-augmented immune therapies
@nl
Role of Toll-like receptors in adjuvant-augmented immune therapies.
@ast
Role of Toll-like receptors in adjuvant-augmented immune therapies.
@en
P2093
P2860
P356
P1476
Role of Toll-like receptors in adjuvant-augmented immune therapies
@en
P2093
Misako Matsumoto
Takashi Akazawa
Tsukasa Seya
P2860
P304
31-8; discussion 133-7
P356
10.1093/ECAM/NEK010
P407
P577
2006-01-30T00:00:00Z